Recent studies have shown that immunotherapies based on immune checkpoint blockage, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, have prominent efficacy against bladder cancer (22, 23). Here, CTLA4 is linked to urinary bladder carcinoma.